Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 1021-1029

  Takikawa, Yasuhiro ^a   Endo, Ryujin ^a   Suzuki, Kazuyuki ^a   Tsubouchi, Hirohito ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Acute liver failure; Model for prognosis prediction; Prothrombin time

Indexed keywords

BILIRUBIN; PARACETAMOL;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; JAPAN; LIVER DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; REGISTRATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ACETAMINOPHEN; ADULT; AGED; COHORT STUDIES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; JAPAN; LIVER FAILURE, ACUTE; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS;

EID: 71549125969     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.09.011     Document Type: Article

References (24)

1. Heathcote J., Elewaut A., Fedail S., Gangl A., Hamid S., Shah M., et al. OMGE practice guideline. Management of acute viral hepatitis. World Gastroenterol News 9 (2004) 1-12
2. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., and Seeff R.B. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 46 (2000) 2050-2068
3. Trey C., Lipworth L., and Chalmers T.C. Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med 279 (1968) 798-801
4. Polson J., and Lee W.M. AASLD position paper. The management of acute liver failure. Hepatology 41 (2005) 1180-1196
5. Rolando N., Wade J., Davalos M., Wedson J., Philpott-Howard J., and William R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32 (2000) 734-739
6. Vaquero J., Polson J., Chung C., Helonowski I., Schiodt F.V., Reisch J., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125 (2003) 755-764
7. Sato S., Suzuki K., Takikawa Y., Endo R., Omata M., and Japanese National Study Group of Fulminant Hepatitis. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res 30 (2004) 155-161
8. Fujiwara K., Mochida S., Matsui A., Nakayama N., Nagoshi S., and Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Summary of 698 patients between 1998 and 2003 analyzed by the annual national survey. Hepatol Res 38 (2008) 646-657
9. Takikawa Y., and Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res 38 (2008) S14-S18
10. Keays R., Harrison P.M., Wendon J.A., Forbes A., Gove C., Alexander G.J., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 303 (1991) 1026-1029
11. Ware A., Jones R., Shorey J., and Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 62 (1974) 130-133
12. Rakela J. A double-blind randomized trial of hydrocortisone in acute hepatic failure. Gastroenterology 76 (1979) 1279
13. Canalese J., Gimson A., Davis C., Mellon P.J., Davis M., and Williams R. Controlled trial of dexamethasone and manitol for the cerenral oedema of fulminant hepatic failure. Gut 23 (1982) 625-629
14. Rake M.O., Flute P.T., Shikin K.B., Lewis M.L., Winch J., and Williams R. Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet 2 (1971) 1215-1218
15. Langley P.G., Hughes R.D., Forbes A., Keays R., and Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol 17 (1993) 326-331
16. Takahashi Y., Shimizu M., and The study group of FH. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicenter study. J Gastroenterol Hepatol 6 (1991) 159-164
17. Takikawa Y., Endo R., Suzuki K., Fujiwara K., and Omata M. The fulminant hepatitis study group of Japan. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci 51 (2006) 359-364
18. Bernuau J. Acute liver failure: avoidance of deleterious cofactors and early specific medical therapy for the liver are better than late intensive care for the brain. J Hepatol 41 (2004) 152-155
19. Ostapowicz G.A., Fontana R.J., Schiodt F.V., Larson A., Davern T.J., and Han S.H. Result of prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 945-954
20. Tygstrup R. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 6 (1986) 129-137
21. O'Grady J.G., Alexander G.J.M., Hayller K.M., and Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-445
22. Robert A., and Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology 24 (2007) 1392-1394
23. Tripodi A., Chantarangkul V., Primignani M., Fabris F., Dell'Era A., Sei C., et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 46 (2007) 520-527
24. Bellest L., Eschwege V., Poupon R., Chazouilleres O., and Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 46 (2007) 528-534